Loyzide M 30mg/500mg Tablet XR is a combination oral antihyperglycemic medication containing Gliclazide 30mg and Metformin 500mg in an extended-release formulation. It is primarily indicated for the management of type 2 diabetes mellitus, particularly in patients who are inadequately controlled on diet and exercise alone or when monotherapy with either agent is insufficient. Gliclazide, a sulfonylurea derivative, acts by stimulating pancreatic beta cells to increase insulin secretion, thereby reducing blood glucose levels. Metformin, a biguanide, improves insulin sensitivity by decreasing hepatic glucose production and enhancing peripheral glucose uptake. The extended-release formulation allows for once-daily dosing, improving patient compliance and maintaining more stable plasma drug concentrations. Loyzide M is typically prescribed alongside lifestyle modifications such as diet and exercise to achieve optimal glycemic control. It is contraindicated in patients with severe renal impairment, metabolic acidosis, or known hypersensitivity to its components. Common adverse effects may include gastrointestinal disturbances, hypoglycemia, and, rarely, lactic acidosis. Regular monitoring of blood glucose levels, renal function, and periodic assessment of hematologic parameters are recommended during therapy. This combination therapy offers a synergistic approach to glycemic management in type 2 diabetes, enhancing efficacy while minimizing side effects.